CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON, Mass., Oct. 9, 2023 /PRNewswire/ — CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in […]